Loading company…
SciBrunch Therapeutics develops small-molecule drugs for cancer treatment.
Founded in 2024 and based in Shanghai, SciBrunch Therapeutics develops small-molecule antitumor drugs, using clinically validated targets to build a differentiated drug pipeline. In January 2026, it raised over USD 35 million in Pre-Series A funding led by HighLight Capital, with participation from Suzhou Xincheng Private Equity Fund Management, Elikon Venture, LongRiver Investments, BioTrack Capital and Hankang Capital. The funding will support clinical development of SPR1020 and RAS inhibitor programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in